American Journal of Psychiatry Audio
June 2024: Long-Term Course of Remission and Recovery in Psychotic Disorders
Jun 1, 2024
Sara Tramazzo, a specialist from Stony Brook University, discusses the long-term outcomes for patients with psychotic disorders, revealing lower recovery rates compared to other studies. She highlights challenges in tracking patients over 25 years and the importance of differentiating between recovery and remission. Dr. Ned Kalin joins later to explore innovative treatment approaches and the potential use of neuromelanin as a biomarker in first-episode schizophrenia. Together, they shed light on the complex landscape of long-term psychiatric care.
29:23
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The study reveals that patients with schizophrenia experience a consistent decline in recovery and remission rates over a 25-year follow-up period.
- Clinical implications highlight the need for long-term care strategies tailored for schizophrenia patients, contrasting with the fluctuating recovery patterns in other psychotic disorders.
Deep dives
Long-Term Declines in Remission and Recovery Rates
The study highlights a concerning trend in the long-term remission and recovery rates among patients with schizophrenia. Over a 25-year follow-up period, the research indicates that individuals diagnosed with schizophrenia experience progressively lower rates of recovery and remission compared to other psychotic disorders. While persons with other psychotic disorders show an intermittent pattern of recovery, schizophrenia patients demonstrate a consistent decline in recovery rates at each follow-up point. This contrasts with findings from some previous studies, emphasizing the significance of using a comprehensive epidemiological approach to assess long-term outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
